Literature DB >> 21982792

Validated liquid chromatographic method and analysis of content of tilianin on several extracts obtained from Agastache mexicana and its correlation with vasorelaxant effect.

Oswaldo Hernández-Abreu1, Liliana Durán-Gómez, Roberto Best-Brown, Rafael Villalobos-Molina, Julio Rivera-Leyva, Samuel Estrada-Soto.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: To optimize the obtention of tilianin, an antihypertensive flavonoid isolated from Agastache mexicana (Lamiaceae), a medicinal plant used in Mexico for the treatment of hypertension. Also, a validated HPLC method to quantify tilianin from different extracts, obtained by several extraction methods, was developed.
MATERIALS AND METHODS: The aerial parts of Agastache mexicana were dried at different temperatures (22, 40, 50, 90, 100 and 180°C) and the dry material was extracted with methanol by maceration to compare the content of the active constituent tilianin in the samples. Furthermore, EtOH:H(2)O (7:3), infusion and decoction extracts were prepared from air-dried samples at room temperature to compare the content and composition of the different extraction methods. Moreover, an ex vivo vasorelaxant test on endothelium-intact aortic rat rings was conducted, in order to correlate the presence of tilianin with the activity of each extract.
RESULTS: Higher concentration and amounts of tilianin were determined from chromatograms in the obtained methanolic extracts from plant material dried at 90, 50, 40 and 22°C, followed by 100°C; however, lower concentrations were observed in dried at 180°C and EtOH:H(2)O (7:3). It is worth to notice that methanolic extracts with higher amount of tilianin were the most potent vasorelaxant extracts, even though these extracts were less potent than carbachol, a positive control used. Finally, decoction, infusion and EtOH:H(2)O (7:3) extracts did not show any vasorelaxant effect.
CONCLUSION: Results suggest that extracts with higher concentration of tilianin possess the best vasorelaxant activity, which allowed us to have a HPLC method for future quality control for this medicinal plant.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21982792     DOI: 10.1016/j.jep.2011.09.041

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

Review 1.  The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders.

Authors:  Giovanna Felipe Cavalcante E Costa; Hisao Nishijo; Leonardo Ferreira Caixeta; Tales Alexandre Aversi-Ferreira
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-02       Impact factor: 2.629

2.  Volatilomic Analysis of Four Edible Flowers from Agastache Genus.

Authors:  Basma Najar; Ilaria Marchioni; Barbara Ruffoni; Andrea Copetta; Luisa Pistelli; Laura Pistelli
Journal:  Molecules       Date:  2019-12-06       Impact factor: 4.411

Review 3.  Tilianin: A Potential Natural Lead Molecule for New Drug Design and Development for the Treatment of Cardiovascular Disorders.

Authors:  Farrah Syazana Khattulanuar; Mahendran Sekar; Shivkanya Fuloria; Siew Hua Gan; Nur Najihah Izzati Mat Rani; Subban Ravi; Kumarappan Chidambaram; M Yasmin Begum; Abul Kalam Azad; Srikanth Jeyabalan; Arulmozhi Dhiravidamani; Lakshmi Thangavelu; Pei Teng Lum; Vetriselvan Subramaniyan; Yuan Seng Wu; Kathiresan V Sathasivam; Neeraj Kumar Fuloria
Journal:  Molecules       Date:  2022-01-20       Impact factor: 4.411

Review 4.  A Systematic Approach to Agastache mexicana Research: Biology, Agronomy, Phytochemistry, and Bioactivity.

Authors:  Mariana Palma-Tenango; Rosa E Sánchez-Fernández; Marcos Soto-Hernández
Journal:  Molecules       Date:  2021-06-20       Impact factor: 4.411

Review 5.  Phytochemistry and bioactivity of aromatic and medicinal plants from the genus Agastache (Lamiaceae).

Authors:  Sylwia Zielińska; Adam Matkowski
Journal:  Phytochem Rev       Date:  2014-04-03       Impact factor: 5.374

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.